BACKGROUND: Nonsmall cell lung carcinomas (NSCLCs) are associated with very dismal prognoses, and adjuvant chemotherapy, including irinotecan, taxanes, platin, and vinca alkaloid derivatives, offer patients only slight clinical benefits. Part of the chemoresistance of NSCLC results from the expression in NSCLC cells of a very large set of endogenous proteins, which antagonize chemotherapy-mediated attacks on these tumor cells. METHODS: The authors set up an orthotopic model of a human NSCLC by grafting A549 cells into the lungs of nude mice. They tried treating these A549 NSCLC orthotopic xenograft-bearing nude mice on the basis of various chemotherapeutic protocols, including chronic administrations of taxol, oxaliplatin, and irinotecan. A...
International audienceBackground: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) ...
Histone deacetylase inhibitor (HDACi; vorinostat) responses were studied in murine and human lung ca...
Background: Non-small cell lung cancer (NSCLC) accounts for 81% of all cases of lung cancer and they...
A pharmacologically relevant modelling was attempted for screening of new molecules potentially acti...
Introduction: Lung cancer leads in mortality among all types of cancer in US and Non-small cell lung...
Introduction: Lung cancer leads in mortality among all types of cancer in US and Non-small cell lung...
IntroductionAlthough subcutaneous xenograft models have been widely used to evaluate the antitumor a...
We examined the tumorigenic and metastatic potentials of three human non-small cell lung cancer (NSC...
BACKGROUND: Diethylnitrosamine is a well known carcinogen that induces cancers of various organs in ...
Lung cancer leads in mortality among all types of cancer in the US and Non-small cell lung cancer (N...
Background:Currently, the identification of accurate biomarkers for the diagnosis of patients with e...
There is a paucity of adequate mouse models and cell lines available to study lung squamous cell car...
International audienceBackground: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) ...
AbstractWe examined the tumorigenic and metastatic potentials of three human non-small cell lung can...
Histone deacetylase inhibitor (HDACi; vorinostat) responses were studied in murine and human lung ca...
International audienceBackground: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) ...
Histone deacetylase inhibitor (HDACi; vorinostat) responses were studied in murine and human lung ca...
Background: Non-small cell lung cancer (NSCLC) accounts for 81% of all cases of lung cancer and they...
A pharmacologically relevant modelling was attempted for screening of new molecules potentially acti...
Introduction: Lung cancer leads in mortality among all types of cancer in US and Non-small cell lung...
Introduction: Lung cancer leads in mortality among all types of cancer in US and Non-small cell lung...
IntroductionAlthough subcutaneous xenograft models have been widely used to evaluate the antitumor a...
We examined the tumorigenic and metastatic potentials of three human non-small cell lung cancer (NSC...
BACKGROUND: Diethylnitrosamine is a well known carcinogen that induces cancers of various organs in ...
Lung cancer leads in mortality among all types of cancer in the US and Non-small cell lung cancer (N...
Background:Currently, the identification of accurate biomarkers for the diagnosis of patients with e...
There is a paucity of adequate mouse models and cell lines available to study lung squamous cell car...
International audienceBackground: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) ...
AbstractWe examined the tumorigenic and metastatic potentials of three human non-small cell lung can...
Histone deacetylase inhibitor (HDACi; vorinostat) responses were studied in murine and human lung ca...
International audienceBackground: Osimertinib is a third generation tyrosine kinase inhibitor (TKI) ...
Histone deacetylase inhibitor (HDACi; vorinostat) responses were studied in murine and human lung ca...
Background: Non-small cell lung cancer (NSCLC) accounts for 81% of all cases of lung cancer and they...